A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

NCT01219543 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

47

Enrollment

INDUSTRY

Sponsor class

Stopped Compound development discontinued

Conditions

Solid Tumour
Advanced Solid Malignancies
Child-Pugh A to B7 Advanced Hepatocellular Carcinoma
EGFR and/or ROS Mutant NSCLC
Lung Metastasis Carcinoma
Gastric Cancer

Interventions

DRUG: AZD1480 Daily
DRUG: AZD1480 BID

Sponsor

AstraZeneca